Sonoma Pharmaceuticals (SNOA) Other Non-Current Assets (2011 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Other Non-Current Assets came in at $64000.0 in Q1 2026, down 13.51% year-on-year from $74000.0 in Q1 2025, and little changed quarter-over-quarter from $64000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $64000.0 for Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 13.51% year-over-year to $64000.0 in Q1 2026; TTM through Mar 2026 was $64000.0, a 13.51% decrease from a year earlier, with the FY2026 full-year figure at $64000.0, down 13.51% from the prior year.
- Other Non-Current Assets was little changed at $64000.0 in Q1 2026 per SNOA's latest filing, from $64000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $308000.0 in Q4 2022 and bottomed at $61000.0 in Q2 2024.
- The 5-year median for Other Non-Current Assets is $76000.0 (2024), against an average of $98823.5.
- Across the five-year window, Other Non-Current Assets soared 310.67% in 2022 and plunged 74.68% in 2023, its largest moves.
- Year by year, Other Non-Current Assets stood at $308000.0 in 2022, then plunged by 74.68% to $78000.0 in 2023, then slipped by 6.41% to $73000.0 in 2024, then dropped by 12.33% to $64000.0 in 2025, then changed by 0.0% to $64000.0 in 2026.
- Per Business Quant, the three latest SNOA Other Non-Current Assets figures stand at $64000.0 (Q1 2026), $64000.0 (Q4 2025), and $84000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | 64,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Sep 30, 2025 | 84,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Sep 30, 2023 | 75,000.00 |
| Jun 30, 2023 | 77,000.00 |
| Mar 31, 2023 | 73,000.00 |
| Dec 31, 2022 | 308,000.00 |
| Sep 30, 2022 | 238,000.00 |
| Jun 30, 2022 | 112,000.00 |
| Mar 31, 2022 | 77,000.00 |
| Dec 31, 2021 | 75,000.00 |
| Sep 30, 2021 | 76,000.00 |
| Jun 30, 2021 | 114,000.00 |